Led · Seed · Aug 2026

Callosum’s platform sits between applications and hardware, decomposing AI inference workloads, matching sub-tasks to specialised models and processors, and routing execution to the most suitable hardware to balance speed, cost and precision. The company claims up to 4x speed improvements, 70% lower compute costs and a 10% higher task success rate on complex agentic financial workloads compared with running a single frontier model on conventional GPUs. A family of tailored inference APIs is being launched, with some APIs already in production for complex workloads in financial services. Callosum works with a range of silicon and infrastructure partners — including Cerebras, Rebellions, Axelera, Tendrils and Supermicro — and is a founding member of ARIA’s Scaling Inference Lab. The startup was founded by Danyal Akarca and Jascha Achterberg, who met while doing PhDs at Cambridge, and plans to use the new funding to scale the technology, deepen ecosystem partnerships and grow the team.

Led · Series C · Aug 2026

CodeRabbit offers an automated platform that uses AI agents to review freshly generated code in real time, catching syntax errors, logic bugs and security vulnerabilities as code is created. The company has expanded its offering with Agentic Change Management, which includes CodeRabbit Triage for scoring and routing pull requests, Change Stack for visualizing a change's impact on system behavior and dependencies, and CodeRabbit Security for full-repository scanning and continuous monitoring after code ships. Its tools validate incoming pull requests using repository-wide context and sandboxed test environments, and can generate recommended fixes that re-enter the pull request workflow. CodeRabbit has positioned the product to help teams prioritize and govern a rising volume of code changes originating from developers, nontechnical staff and automated agents. The company announced a $143 million Series C to accelerate these product capabilities and scale adoption. Prior investors such as CRV, Scale Venture Partners, Flex Capital and Pelion Venture Partners participated in the latest round.

Participated · Seed · Jul 2026

KISSZU is developing embodied adaptive AI robots aimed at supporting children's development across health and education use cases. The founding team is multidisciplinary and includes a female CTO with a PhD in Robotics and an MIT Innovation Award, and a co-founder who completed a PhD in Robotics and AI at TU Berlin in 2025. The company reports early commercial validation and pilot traction. KISSZU plans to develop hardware and software together, emphasizing prototyping, testing, safety, manufacturing, child-first design and privacy. Financially, the company has just closed a €12M pre-seed round backed by Headline, Atomico, Rerail, Global Founders Capital and a group of notable angel investors. KISSZU will be building from London and focusing on European markets initially.

Participated · Series C · Jul 2026

Neko Health runs the Neko Health Scan, a 60-minute comprehensive, non-invasive, radiation-free assessment that captures millions of health data points using proprietary sensors alongside blood analysis and delivers results with an in-person clinician consultation. Since launching in February 2023, Neko has expanded clinics across Sweden and the U.K., recently opening a new Stockholm clinic and rolling out next-generation devices (Derma-2, Echo-2, Spectrum-2) and body-composition measures. Over 350,000 people have registered for a scan and more than 100,000 members have completed one, with about 75% of members prepaying for a follow-up scan at the end of their appointment. Neko reports measurable health improvements for returning members, including statistically significant improvements in five of seven key biomarkers and many previously severe conditions brought under control. The company is focused on scaling clinic footprint and iterating its in-house tech stack, with planned U.S. expansion and continued investment in hardware and its health data platform.

Led · Seed · Jun 2026

Frontier Health develops an AI agent called Juno that works alongside NHS administrative staff to navigate systems, complete routine tasks such as booking appointments, identify risks, and help keep patients moving through care. Juno escalates to a human operator when it cannot understand a case. The company cites projections that healthcare systems may face a 10 million worker shortfall by 2030 and positions its product as a way to reduce administrative burden. One reported client is East Sussex Healthcare NHS Trust. Frontier Health was founded in 2024 by former Palantir healthcare lead Rachel Finegold and currently has a 12-person team. The startup raised £9.7m in its most recent round, bringing total funding to £11.9m and plans to use proceeds to expand across NHS trusts and grow its team.